Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Common Equity (2017 - 2025)

Historic Common Equity for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $546.5 million.

  • Dianthus Therapeutics' Common Equity rose 6172.16% to $546.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $546.5 million, marking a year-over-year increase of 6172.16%. This contributed to the annual value of $352.5 million for FY2024, which is 10872.68% up from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Common Equity is $546.5 million, which was up 6172.16% from $303.1 million recorded in Q2 2025.
  • Dianthus Therapeutics' Common Equity's 5-year high stood at $546.5 million during Q3 2025, with a 5-year trough of -$61.5 million in Q2 2023.
  • Moreover, its 4-year median value for Common Equity was $178.4 million (2023), whereas its average is $202.8 million.
  • In the last 5 years, Dianthus Therapeutics' Common Equity tumbled by 14529.84% in 2023 and then skyrocketed by 83334.71% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Common Equity (Quarter) stood at -$44.4 million in 2022, then surged by 480.61% to $168.9 million in 2023, then surged by 108.73% to $352.5 million in 2024, then soared by 55.03% to $546.5 million in 2025.
  • Its last three reported values are $546.5 million in Q3 2025, $303.1 million for Q2 2025, and $328.6 million during Q1 2025.